subscribeSubscribe
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
PRESS RELAESE
22 Jun 2023
Share Share
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication

Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
PHARMABIZ
24 Dec 2022
Share Share
J&J gets EMA backing for Imbruvica-venetoclax combination

J&J gets EMA backing for Imbruvica-venetoclax combination
Nick Paul Taylor FIERCEPHARMA
29 Jun 2022
Share Share
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold

TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold
V. Singh YAHOO FINANCE
28 Jan 2022
Share Share
First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab

First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab
CANCERTHERAPYADVISOR
18 Jun 2021
Share Share
IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results

IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results
PRESS RELEASE
14 Jun 2021
Share Share
First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab

First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab
PRNEWSWIRE
12 Jun 2021
Share Share
TG`s leukemia combo clears phase 3, aims for 2020 filing

TG`s leukemia combo clears phase 3, aims for 2020 filing
Amirah Al Idrus FIERCE BIOTECH
05 May 2020
Share Share
FDA lifts hold on AbbVie, Roche`s Venclexta in myeloma

FDA lifts hold on AbbVie, Roche`s Venclexta in myeloma
K. Blankenship Fierce Pharma
25 Jun 2019
Share Share
AstraZeneca`s Calquence sets Imbruvica in its sights

AstraZeneca`s Calquence sets Imbruvica in its sights
Kyle Blankenship FIERCE PHARMA
17 Jun 2019
Share Share